MA30786B1 - Procede d'optimisation de traitement de la leucemie philadelphie positive avec des inhibiteurs de tyrosine kinase abl. - Google Patents
Procede d'optimisation de traitement de la leucemie philadelphie positive avec des inhibiteurs de tyrosine kinase abl.Info
- Publication number
- MA30786B1 MA30786B1 MA31775A MA31775A MA30786B1 MA 30786 B1 MA30786 B1 MA 30786B1 MA 31775 A MA31775 A MA 31775A MA 31775 A MA31775 A MA 31775A MA 30786 B1 MA30786 B1 MA 30786B1
- Authority
- MA
- Morocco
- Prior art keywords
- leukemia
- tyrosine kinase
- abl tyrosine
- cmin
- bcr
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ecology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN PROCÉDÉ DE TRAITEMENT DE LA LEUCÉMIE PHILADELPHIE POSITIVE (PH+), TELLE QUE LA LEUCÉMIE LYMPHOBLASTE AIGUË POSITIVE DU CHROMOSOME DE PHILADELPHIE (PH+ ALL) OU LA LEUCÉMIE MYÉLOÏDE CHRONIQUE (LMC), CHEZ UN PATIENT HUMAIN COMPRENANT LES ÉTAPES SUIVANTES : (A) L'ADMINISTRATION D'UNE QUANTITÉ FIXE PRÉDÉTERMINÉE D'UN INHIBITEUR DE TYROSINE KINASE BCR-ABL, TEL QUE L'IMANITIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI À DES PATIENTS HUMAINS ATTEINTS DE LA LEUCÉMIE PH+, (B) LE PRÉLÈVEMENT D'AU MOINS UN ÉCHANTILLON SANGUIN DESDITS PATIENTS, (C) LA DÉTERMINATION DU NIVEAU DE LA CONCENTRATION PLASMIQUE MINIMALE(CMIN) DE L'INHIBITEUR DE TYROSINE KINASE OU D'UN MÉTABOLITE DE CELUI-CI AINSI QUE DES TAUX MMR, (D) L'ÉVALUATION D'UN POTENTIEL DE DISCRIMINATION DE CONCENTRATIONS DE DÉPRESSION PLASMIQUE POUR MMR ET L'IDENTIFICATION D'UN SEUIL CMIN POUR UNE SENSIBILITÉ ET UNE SPÉCIFICITÉ OPTIMALES ET (E)L'AJUSTEMENT DE LA DOSE DE L'INHIBITEUR DE TYROSINE KINASE BCR-ABL OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI APPLIQUÉ À DES PATIENTS INDIVIDUELS PARMI LADITE POPULATION DE PATIENTS ET, ÉVENTUELLEMENT, DES PATIENTS FUTURS ATTEINTS DE LA LEUCÉMIE PH+ DE SORTE QU'UNE CMIN SOIT ATTEINT DANS CHAQUE PATIENT INDIVIDUEL ÉGAL OU INFÉRIEUR AU CMIN SEUIL OBTENU À L'ÉTAPE (D).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82662206P | 2006-09-22 | 2006-09-22 | |
| US82827806P | 2006-10-05 | 2006-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30786B1 true MA30786B1 (fr) | 2009-10-01 |
Family
ID=39092883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31775A MA30786B1 (fr) | 2006-09-22 | 2009-04-10 | Procede d'optimisation de traitement de la leucemie philadelphie positive avec des inhibiteurs de tyrosine kinase abl. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20090281113A1 (fr) |
| EP (2) | EP2068938B1 (fr) |
| JP (1) | JP5735742B2 (fr) |
| KR (1) | KR20090065512A (fr) |
| AT (1) | ATE495761T1 (fr) |
| AU (1) | AU2007299764B2 (fr) |
| BR (1) | BRPI0717099A2 (fr) |
| CA (1) | CA2662977A1 (fr) |
| CL (1) | CL2007002725A1 (fr) |
| CY (1) | CY1111356T1 (fr) |
| DE (1) | DE602007012122D1 (fr) |
| DK (1) | DK2068938T3 (fr) |
| HR (1) | HRP20110250T1 (fr) |
| IL (1) | IL197296A (fr) |
| MA (1) | MA30786B1 (fr) |
| MX (1) | MX2009003082A (fr) |
| NO (1) | NO20091490L (fr) |
| NZ (1) | NZ575113A (fr) |
| PL (1) | PL2068938T3 (fr) |
| PT (1) | PT2068938E (fr) |
| TN (1) | TN2009000094A1 (fr) |
| TW (1) | TWI398251B (fr) |
| WO (1) | WO2008036792A2 (fr) |
| ZA (1) | ZA200901220B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2237783B1 (fr) * | 2008-01-23 | 2014-11-19 | Novartis AG | Procédé d'optimisation du traitement de maladies prolifératives à médiation par récepteur à tyrosine kinase kit avec de l'imatinib |
| JP2012510470A (ja) * | 2008-12-01 | 2012-05-10 | ノバルティス アーゲー | メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法 |
| US20110046919A1 (en) | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
| FR2943418A1 (fr) * | 2009-03-17 | 2010-09-24 | Centre Nat Rech Scient | Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications |
| EP3072964A1 (fr) * | 2013-11-22 | 2016-09-28 | National Center For Child Health And Development | Nouveau gène chimère atf7ip-pdgfrb pour la leucémie lymphoblastique aiguë |
| JP6691558B2 (ja) | 2015-07-07 | 2020-04-28 | コデクシス， インコーポレイテッド | 改善された活性を持つ新規のｐ４５０−ｂｍ３バリアント |
| IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
| CN114994213A (zh) * | 2022-06-28 | 2022-09-02 | 北京赛诺浦生物技术有限公司 | 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| CA2366932C (fr) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Inhibiteurs cycliques de proteine tyrosine kinase |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| EP1497463A1 (fr) * | 2002-04-17 | 2005-01-19 | Novartis AG | Procedes permettant de prevoir la faculte de reponse de patients a des inhibiteurs de tyrosine kinase |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| MXPA06014247A (es) | 2004-06-10 | 2007-03-12 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina quinasa. |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
-
2007
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/fr not_active Ceased
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 EP EP07842842A patent/EP2068938B1/fr not_active Not-in-force
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 CA CA002662977A patent/CA2662977A1/fr not_active Abandoned
- 2007-09-20 EP EP10171365A patent/EP2251042A3/fr not_active Withdrawn
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
-
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
-
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
-
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111356T1 (el) | Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl | |
| EA201190042A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| BRPI0508286A (pt) | métodos para determinar a possibilidade de efetividade de um tratamento seletivo de receptor de fator de crescimento epidérmico em um paciente, para tratar um paciente e para selecionar um composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, sonda, kit, composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, composição farmacêutica, ácido nucléico e proteìna isolada | |
| KR20220108201A (ko) | 수면 개선 방법 | |
| Ortiz-Comino et al. | Factors influencing quality of life in survivors of head and neck cancer: A preliminary study | |
| BRPI0518795A2 (pt) | mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio | |
| RU2010101634A (ru) | Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi | |
| DK1843757T3 (da) | Behandling af fantomfænomener | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| US8697702B2 (en) | Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate | |
| RU2011122721A (ru) | Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl | |
| Nawangwulan et al. | Determinants of Hypertension Incidence in Individuals Aged≥ 40 Years in the Work Area of the Meranti Health Center, Merangin Regency 2021 | |
| TW200507828A (en) | Method for treatment of chemotherapy-induced diarrhea | |
| JP5881671B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| Coluzzi et al. | WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS | |
| CN102526734A (zh) | 治疗年龄相关性听力损失的药物组合物及其应用 | |
| ATE312612T1 (de) | Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen | |
| RU2483732C2 (ru) | СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ | |
| Gagolewicz | Neuromodulatory and metaplastic regulation of long-term synaptic plasticity in the primary visual cortex of adult rats | |
| Maroni et al. | ACHIEVEMENT OF LIPID TARGETS IN NON ALCOHOLIC FATTY LIVER DISEASE DURING STATIN TREATMENT: PP. 33.324 | |
| Azhary et al. | The Assessment Of Different Level Of Tissue Inhibitor Of Metalloproteinase (TIMP)-1 From Periodontal Fluid Among Smokers | |
| Nair et al. | ASSOCIATIONS BETWEEN BLOOD PRESSURE CONTROL AND WELLBEING IN PRIMARY CARE PRACTICE: PP. 33.325 | |
| Alihosseini et al. | The mechanism of miR-133a in OSCC | |
| Dong | Gene expression and neural hyperactivity after unilateral hearing loss |